Free Trial
TSE:HBP

Helix BioPharma Q2 2026 Earnings Results & Report

Helix BioPharma logo
C$0.96 0.00 (0.00%)
As of 10/13/2026 03:46 PM Eastern

Helix BioPharma reported Q2 2026 earnings on March 16, 2026. The company reported EPS of -C$0.01.

Earnings Announcement Details

Quarter
Q2 2026
Report Date
Time
After Market Closes

Helix BioPharma EPS Results

Actual EPS
-C$0.01
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Helix BioPharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Helix BioPharma Q2 2026 Earnings FAQ

Helix BioPharma (TSE:HBP) reported earnings of -C$0.01 per share for Q2 2026. The report was announced on Monday, March 16, 2026.

Helix BioPharma Earnings Headlines

Off-market insider selling at Helix BioPharma (HBP)
Why major institutions are piling into this digital asset now
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one that gets burned with every transaction on what analysts are calling America's new financial grid. The Nasdaq has received SEC approval to move stocks onto blockchain rails, and BlackRock CEO Larry Fink dedicated his entire 2026 annual letter to this infrastructure shift. Blockchain analyst Andy Howard is calling this asset 'Digital Oil' - and says institutional buyers are already positioned.tc pixel
HBP.TO - | Stock Price & Latest News | Reuters
Kurs Helix BioPharma Corp.
See More Helix BioPharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Helix BioPharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Helix BioPharma and other key companies, straight to your email.

About Helix BioPharma

Helix BioPharma (TSE:HBP) is an oncology company that innovates from strength to bring near-term solutions for today's hardest-to-treat cancers. The Company's pipeline is led by Tumor Defense Breaker¿ L-DOS47, a clinical-stage antibody-enzyme conjugate designed to prime CEACAM6-expressing tumors for increased sensitivity to therapy and augment the effectiveness of today's front-running anti-cancer treatments. L-DOS47 has completed Phase Ib studies in non-small cell lung cancer (NSCLC) and shares its CEACAM6-targeting foundation with Helix's next-generation bi-specific antibody-drug conjugates (ADCs), currently in discovery. The Company also advances two pre-IND candidates: (i) LEUMUNA¿, an oral immune checkpoint modulator aimed at achieving durable remission in post-transplant leukemia relapse, and (ii) GEMCEDA¿, a first-in-class oral gemcitabine prodrug with bioavailability on a par with IV, designed to expand treatment options for advanced cancers.

View Helix BioPharma Profile